中國生物製藥(01177.HK)2024年度盈利增長約50.1% 創新產品收入達120.6億元
格隆匯3月20日丨中國生物製藥(01177.HK)發佈公告，截至2024年12月31日止年度，集團錄得收入約人民幣2,886,616萬元，較去年同期增長約10.2%。毛利約人民幣2,352,994萬元，較去年同期增長約10.9%。中藥現代製劑及西藥業務分部的毛利約爲人民幣2,345,000萬元，較去年同期增長約11.0%。其他業務分部的毛利合計約爲人民幣7,994萬元，較去年同期減少約5.6%。
歸屬於母公司持有者盈利約人民幣349,983萬元，較去年增長約50.1%。歸屬於母公司持有者盈利同比顯著增長主要受惠於本年度收入明顯增長及錄得出售附屬公司收益。扣除已終止經營業務的歸屬於母公司持有者應佔盈利，應佔聯營公司及合營公司虧損（扣除相關稅項及非控制權益），若幹資產及負債的公允價值變動及一次性調整的減值，流動權益投資的公允價值虧損╱（利潤）（扣除相關稅項及非控制權益），股權激勵費用（扣除相關稅項及非控制權益），可轉換債券債務部份的利息費用及匯兌（收益）╱虧損的影響後，經調整非《香港財務報告準則》歸母淨利潤約人民幣345,696萬元，較去年同期增長約33.5%。董事會建議派發年度末期股息每股普通股4港仙（2023年：3港仙）。
於報告期間內，集團共有6個創新產品獲中國國家藥品監督管理局（NMPA）批準上市，分別爲安得衛（貝莫蘇拜單抗注射液）、安柏尼（富馬酸安奈克替尼膠囊）、安洛晴（枸櫞酸依奉阿克膠囊）、安方寧（格索雷塞片）、帕樂坦（帕妥珠單抗注射液）和貝樂林（利拉魯肽注射液），其中4個爲國家1類創新藥，是2024年獲批1類創新藥數量最多的企業。2024年，集團創新產品收入達到人民幣120.6億元，同比增長21.9%。除創新產品外，集團還有28個仿製藥獲NMPA批準上市，整體仿製藥收入在2024年實現正增長。新產品是驅動集團收入增長的重要動力，2024年集團5年內上市的新產品收入達到人民幣100.9億元，同比增長25.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
